Here's Why You Should Retain AMED Stock in Your Portfolio Now

Amedisys’ (AMED) continuously improving clinical quality for patients, demonstrated through high Quality of Patient Care and Patient Satisfaction star ratings, is poised to drive growth in the upcoming quarters. The company’s valuable partnership and acquisition are expected to generate significant synergies. However, a dull macroeconomic scenario and fierce competitive pressure may restrict Amedisys’ growth potential.In the past year, this Zacks Rank #3 (Hold) company’s shares have risen 0.4% compared with ...